Rifaximin and loperamide
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Travelers' Diarrhea
Conditions
Travelers' Diarrhea
Trial Timeline
Jun 1, 2004 → Aug 1, 2005
NCT ID
NCT00292344About Rifaximin and loperamide
Rifaximin and loperamide is a approved stage product being developed by Bausch Health for Travelers' Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT00292344. Target conditions include Travelers' Diarrhea.
What happened to similar drugs?
0 of 1 similar drugs in Travelers' Diarrhea were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00292344 | Approved | Completed |
Competing Products
1 competing product in Travelers' Diarrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rifaximin (Sandoz GmbH) tablet + Rifaximin (Xifaxan) + Placebo | Sandoz Group | Phase 3 | 29 |